SkyQuest Technology Group recently introduced Influenza Vaccine Market study with in-depth overview, describing about the Product/Industry Scope and elaborates market outlook and status (2025-2032). The market Study is segmented by key regions which is accelerating the marketization. The Influenza Vaccine Market has witnessed Excellent growth over the past decade and is expected to maintain its upward trajectory.
Influenza Vaccine Market size was valued at USD 7.91 Billion in 2023 and is poised to grow from USD 8.46 Billion in 2024 to USD 14.52 Billion by 2032, growing at a CAGR of 6.98% during the forecast period (2025-2032).
The influenza virus circulates continue indefinitely, causing regional epidemics and outbreaks that have resulted in thousands of deaths. For instance, according to data from the Centers for Disease Control and Prevention (CDC), more than 13 million flu cases have been recorded in the 2019-20 timeframe. The changing nature of the virus necessitates an annual change in the vaccine strain to match the influenza virus strain around the world. During the forecasted period, the increasing prevalence of influenza epidemics and seasonal outbreaks is expected to boost product sales.
Get a Free Sample PDF of the Report – https://www.skyquestt.com/sample-request/Influenza-vaccine-market
In the current market scenario, there are numerous licensed seasonal influenza vaccines recommended by the World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), and other governmental organizations to help fight the disease. Governments have focused on encouraging people to get vaccinated as soon as possible to provide the best possible protection during flu season. Furthermore, pharmaceutical companies are constantly confronted with new challenges in developing a suitable vaccine against a specific strain. As a result, rising demand for effective flu vaccines is expected to drive the Influenza Vaccine Market market.
Detailed Segmentation and Classification of the report (Market Size and Forecast – 2032, Y-o-Y growth rate, and CAGR):
The Influenza Vaccine Market can be segmented based on several factors, including product type, application, end-user, and distribution channel.
Type
Inactivated, and Live Attenuated
Indication
Quadrivalent, Trivalent
Route of administration
Injection, and Nasal Spray
Age group
Pediatric, and Adult
Distribution Channel
Hospital & Pharmacies, Government & Institutional Supply, Others
Influenza Vaccine Market – Regional Analysis:
– Influenza Vaccine North America Market includes (Canada, Mexico, USA)
– Influenza Vaccine Europe Market includes (Germany, France, Great Britain, Italy, Spain, Russia)
– Influenza Vaccine Asia-Pacific Market includes (China, Japan, India, South Korea, Australia)
– Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa)
– Influenza Vaccine South America Market includes (Brazil, Argentina)
– Influenza Vaccine Oceania Market (Australia & New Zealand)
Top Market Players in Influenza Vaccine Market are:
GSK plc (U.K.)
Pfizer Inc. (U.S.)
Vaxess Technologies Inc. (U.S.)
Merck & Co., Inc. (U.S.)
Viatris Inc. (U.S.)
OSIVAX (France)
AstraZeneca (U.K.)
SINOVAC (China)
CSL Limited (Australia)
Emergent BioSolutions Inc. (U.S.)
Emergex Vaccines (U.K.)
Sanofi (France)
BIKEN Co., Ltd. (Japan)
Abbott (U.S.)
Altimmune Inc. (U.S.)
Baxter International Inc. (U.S.)
BioDiem Ltd (Australia)
BiondVax Pharmaceuticals Ltd. (Israel)
F. Hoffmann-La Roche Ltd. (Switzerland)
FluGen Inc. (U.S.)
Mitsubishi Chemical Group Corp. (Japan)
Novavax Inc. (U.S.)
Otsuka Holdings Co. Ltd. (Japan)
Shijiazhuang Yiling Pharmaceutical Co., Ltd. (China)
SK Chemicals Co., Ltd. (South Korea)
Influenza Vaccine Market Recent Developments:
In June 2022, Sanofi restructured its immuno-oncology collaboration with Regeneron Pharmaceuticals, Inc. Regeneron will have worldwide exclusive licensing rights to Libtayo under the modified and restated license and partnership agreement.
In May 2022, GSK plc announced that it has entered into a final agreement to acquire Affinivax, Inc. (Affinivax), a clinical-stage biopharmaceutical business located in Cambridge, Boston, Massachusetts, for a $2.1 billion upfront payment and up to $1.2 billion in possible development milestones.
In May 2021, During the pandemic, Australia launched a national flu vaccination programme to reduce the population’s infection rate. As a result, seasonal vaccines are now available in Australia through community pharmacies and general practitioners.
In March 2021, Sanofi announced USD 736.9 million investment in its Canadian vaccine facility to increase supply of influenza vaccines in Canada, the United States, and Europe. With the goal of increasing supply in these countries, this facility will provide additional antigen and filling capacity for Sanofi’s Fluzone High-Dose Quadrivalent influenza vaccine.
Also Read –
https://pando.life/article/386380
http://prsync.com/skyquest-technology-consulting-pvt-ltd/the-future-of-construction-growth-trends-in-construction-chemicals–ready-mix-concrete-markets-4692286/
Forward-Looking Insights
The Influenza Vaccine Market is set to experience sustained growth, fueled by technological advancements, broader market access, and rising industry demand. With the industry addressing emerging challenges and capitalizing on new opportunities, it is expected to drive innovation and play a pivotal role in advancing health and economic progress.
About Company:
SkyQuest is an IP focused Research and Investment Bank and Accelerator of Technology and assets. We provide access to technologies, markets and finance across sectors viz. Life Sciences, CleanTech, AgriTech, NanoTech and Information & Communication Technology.
We work closely with innovators, inventors, innovation seekers, entrepreneurs, companies and investors alike in leveraging external sources of R&D. Moreover, we help them in optimizing the economic potential of their intellectual assets. Our experiences with innovation management and commercialization have expanded our reach across North America, Europe, ASEAN and Asia Pacific.
Contact Details:
SkyQuest Technology Group
USA (+1) 351-333-4748
Email: [email protected]
